Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy

Area of Science:

• Neuroscience
• Genetics
• Pediatric Neurology

Background:

• Neuronal ceroid lipofuscinoses (NCLs) are inherited neurodegenerative lysosomal storage diseases, representing the most common cause of dementia in children.
• Patients exhibit severe symptoms including visual impairment, cognitive and motor decline, epilepsy, and premature death.
• Currently, only one therapy is approved for CLN2 disease, leaving many NCL types without treatment options.

Purpose of the Study:

• To review the genetics of each NCL disease.
• To discuss the current understanding of potential therapeutics based on pre-clinical and clinical studies.
• To highlight the need for research into treatments for NCL types lacking therapeutic investigation.

Main Methods:

• Review of existing literature on NCL genetics and therapeutic interventions.
• Analysis of pre-clinical and clinical study data for various treatment modalities.
• Examination of experimental animal models used in NCL research.

Main Results:

• Multiple therapeutic strategies including enzyme replacement, stem cell, gene, and pharmacological therapies have been evaluated for various NCL types.
• Cerliponase alpha is the only approved therapy, specifically for CLN2 disease.
• No studies are available for potential treatments for CLN4, CLN9, CLN12, CLN13, or CLN14 diseases.
• Combination therapies may slow disease progression, but complete reversal of NCL is currently unlikely.

Conclusions:

• Early diagnosis and timely initiation of therapy during asymptomatic stages are critical for managing NCL.
• While therapeutic development is progressing, significant gaps remain, particularly for certain NCL subtypes.
• Further research is essential to develop effective treatments for all forms of NCL, with a focus on halting or reversing disease progression.